STM2457 Inhibits the Invasion and Metastasis of Pancreatic Cancer by Down-Regulating BRAF-Activated Noncoding RNA...

Area of Science:

• Oncology
• Molecular Biology
• RNA Biology

Background:

• Pancreatic cancer is a deadly malignancy with poor patient prognosis.
• BRAF-activated noncoding RNA (BANCR) is implicated in pancreatic cancer invasion and metastasis.
• N6-methyladenosine (m6A) methylation influences BANCR levels and pancreatic cancer progression.

Purpose of the Study:

• To investigate the role of METTL3 inhibition by STM2457 on BANCR m6A methylation.
• To evaluate the impact of STM2457 on pancreatic cancer cell proliferation, invasion, and metastasis.

Main Methods:

• RT-qPCR and MeRIP-PCR were used to assess BANCR expression and m6A modification.
• Western blot analysis detected methyltransferase-like 3 (METTL3) expression in tumor tissues.
• In vitro assays examined the effects of STM2457 on pancreatic cancer cell behaviors.

Main Results:

• BANCR was overexpressed in pancreatic cancer tissues and cells, correlating with poor clinical outcomes.
• m6A modification was enriched in BANCR, enhancing its expression.
• STM2457 significantly inhibited pancreatic cancer cell proliferation, invasion, and metastasis by reducing BANCR m6A modification.

Conclusions:

• BANCR is a promising diagnostic and therapeutic target for pancreatic cancer.
• STM2457 shows therapeutic potential by targeting BANCR m6A methylation and inhibiting pancreatic cancer progression.